Atara Biotherapeutics, Inc. said it entered into an amendment to its December 20, 2022 Purchase and Sale Agreement with a fund managed by HealthCare Royalty (HCRx). Under the amendment, HCRx agreed to extend the due date of a one-time $9.0 million cash payment tied to achievement of a milestone under Atara’s Amended and Restated Commercialization Agreement with Pierre Fabre Medicament from June 30, 2026 to January 1, 2028. In connection with the amendment, Atara issued a warrant to purchase up to 400,000 shares of common stock at an exercise price of $0.0001 per share, exercisable immediately with no expiration date, subject to a beneficial ownership limit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260223341002) on February 23, 2026, and is solely responsible for the information contained therein.